DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Anoma Ranaweera, Staff Writer, 2012. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Updated June 2018. Copy edited by Gus Mitchell.
ERIVANCE BCC was an international, single-arm, multicentre, two-cohort, open-label Phase II study that enrolled 104 patients with advanced BCC, including locally advanced BCC (n = 71) and metastasized BCC (33).
Locally advanced BCC patients had lesions that were inappropriate for surgery (inoperable, or for whom surgery would result in substantial deformity) and for which radiotherapy was unsuccessful or contraindicated.
Metastasised BCC was defined as BCC that had spread to other parts of the body, including the lymph nodes, lungs, bones and/or internal organs.
The 31 study sites were located in the United States, Australia and Europe. Study participants received 150mg vismodegib orally, once daily until disease progression or intolerable toxicity.
The primary analysis was conducted 9 months after completion of accrual.
The trial showed that vismodegib substantially shrank tumours or healed visible lesions (objective response rate, or ORR) in 43% of patients with locally advanced BCC and 30% of patients with metastatic BCC, as assessed by independent review, the primary endpoint of the study.
The median progression-free survival (PFS) by independent review for both metastatic and locally advanced BCC patients was 9.5 months.
In addition, the clinical benefit rate (defined as patients who had a clinical response as well as those who experienced disease stability for more than 24 weeks) was 75% in patients treated with vismodegib.
In these patients, vismodegib shrank tumours or healed visible lesions, or prevented them from growing any further for more than 24 weeks.
The ORR as assessed by study investigators, a secondary endpoint, was 60% for locally advanced BCC and 46% for metastatic BCC.
Key results are tabulated below.
|Parameter||Metastatic basal cell carcinoma
(n = 33 evaluable patients)
|Locally-advanced basal cell carcinoma
(n = 63 evaluable patients)
|Objective response rate, n (%)||10 (30.3)
[95% CI: 15.6, 48.2]
[95% CI: 30.5, 56.0]
|Complete response, n (%)||0||13 (20.6)|
|Partial response, n (%)||10 (30.3)||14 (22.2)|
|Median response duration (months)||7.6
[95% CI: 5.6. not estimated]
[95% CI: 5.7, 9.7]
In the metastatic BCC cohort, tumour response was assessed according to the Response Evaluation Criteria in Solid tumours (RECIST) version 1.0.
RECIST is a set of published rules that define when cancer patients improve ("respond"), stay the same ("stabilise"), or worsen ("disease progression") during treatments.
The criteria were published in February 2000 by an international collaboration including the European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.
In the locally advanced BCC cohort, tumour response evaluation included measurement of the externally assessable tumour (including scar), assessment for ulceration in photographs, radiographic assessment of target lesions (if appropriate), and tumour biopsy.
Disease progression was defined as any of the following:
Objective response in locally advanced BCC required at least one of the following criteria and absence of any criterion for disease progression:
Complete response in locally advanced BCC was defined as objective response (as defined above) with no residual BCC on sampling tumour biopsy.
The primary analysis of STEVIE demonstrated that:
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.